Skip to main content

Advertisement

SpringerLink
Log in

Oral antiplatelet drugs in patients with chronic kidney disease (CKD): a review

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Oral Antiplatelet Drugs (OAD) have a proven track record in the risk reduction of major cardiovascular events in patients with cardiovascular disease and normal kidney function. However, major gaps exist in our understanding of their effects on thrombosis and bleeding in chronic kidney disease (CKD). Clinical practice guidelines are ambiguous about use of such drugs in CKD patients, because patients with moderate to severe CKD were systematically excluded from clinical trials evaluating the efficacy and safety of OAD. Paradoxically, CKD patients are at high risk of thrombosis and major bleeding events. Thus, choosing the right combination of OAD for cardiovascular protection in these patients is challenging. Patients with CKD exhibit high rates of OAD hyporesponsiveness. It is, therefore, imperative to explore the mechanisms responsible for poor response to OAD in CKD patients in order to use these drugs more safely and effectively. This review explores suggested mechanisms of platelet dysfucntion in CKD patients and the available evidence on the efficacy and safety of oral antiplatelet drugs in patients with renal dysfunction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hoerger TJ et al (2015) The future burden of CKD in the United States: a simulation model for the CDC CKD initiative. Am J Kidney Dis 65(3):403–411

    Article  PubMed  Google Scholar 

  2. Coresh J et al (2007) Prevalence of chronic kidney disease in the United States. JAMA 298(17):2038–2047

    Article  CAS  PubMed  Google Scholar 

  3. Tsai TT et al (2011) Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. J Am Coll Cardiol 58(18):1859–1869

    Article  CAS  PubMed  Google Scholar 

  4. Go AS et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351(13):1296–1305

    Article  CAS  PubMed  Google Scholar 

  5. Anavekar NS et al (2004) Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351(13):1285–1295

    Article  CAS  PubMed  Google Scholar 

  6. Rao SV et al (2013) An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: a report using an expanded bleeding definition from the National Cardiovascular Data Registry CathPCI Registry. JACC Cardiovasc Interv 6(9):897–904

    Article  PubMed  Google Scholar 

  7. Baber U et al (2015) Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. Circ Cardiovasc Interv 8(6):e001683

    Article  PubMed  Google Scholar 

  8. Jain N et al (2013) Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence? Clin J Am Soc Nephrol 8(4):665–674

    Article  CAS  PubMed  Google Scholar 

  9. Levey AS et al (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139(2):137–147

    Article  PubMed  Google Scholar 

  10. Shlipak MG et al (2002) Cardiovascular disease risk status in elderly persons with renal insufficiency. Kidney Int 62(3):997–1004

    Article  PubMed  Google Scholar 

  11. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31–41

    Article  CAS  PubMed  Google Scholar 

  12. Levey AS et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461–470

    Article  CAS  PubMed  Google Scholar 

  13. Amsterdam EA et al (2014) 2014 AHA/ACC guideline for the management of patients with Non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64(24):e139–e228

    Article  PubMed  Google Scholar 

  14. Amsterdam EA et al (2014) 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 130(25):2354–2394

    Article  PubMed  Google Scholar 

  15. Melloni C et al (2008) Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 51(10):991–996

    Article  PubMed  Google Scholar 

  16. Boccardo P, Remuzzi G, Galbusera M (2004) Platelet dysfunction in renal failure. Semin Thromb Hemost 30(5):579–589

    Article  CAS  PubMed  Google Scholar 

  17. Gafter U et al (1987) Platelet count and thrombopoietic activity in patients with chronic renal failure. Nephron 45(3):207–210

    Article  CAS  PubMed  Google Scholar 

  18. Linthorst GE et al (2002) Plasma thrombopoietin levels in patients with chronic renal failure. Hematol J 3(1):38–42

    Article  CAS  PubMed  Google Scholar 

  19. Dewanjee MK et al (1994) In vitro and in vivo evaluation of the comparative thrombogenicity of cellulose acetate hemodialyzers with radiolabeled platelets. ASAIO J 40(1):49–55

    CAS  PubMed  Google Scholar 

  20. Remuzzi G et al (1983) Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect. J Clin Invest 71(3):762–768

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Di Minno G et al (1985) Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 79(5):552–559

    Article  CAS  PubMed  Google Scholar 

  22. Mezzano D et al (1996) Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost 76(3):312–321

    CAS  PubMed  Google Scholar 

  23. Sloand EM et al (1991) Reduction of platelet glycoprotein Ib in uraemia. Br J Haematol 77(3):375–381

    Article  CAS  PubMed  Google Scholar 

  24. Zwaginga JJ et al (1990) High von Willebrand factor concentration compensates a relative adhesion defect in uremic blood. Blood 75(7):1498–1508

    CAS  PubMed  Google Scholar 

  25. Sreedhara R, Itagaki I, Hakim RM (1996) Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors. Am J Kidney Dis 27(3):355–364

    Article  CAS  PubMed  Google Scholar 

  26. Ibrahim H et al (2016) Detection and quantification of circulating immature platelets: agreement between flow cytometric and automated detection. J Thromb Thrombolysis 42:77–83

    Article  CAS  PubMed  Google Scholar 

  27. Fager AM et al (2010) Properties of procoagulant platelets: defining and characterizing the subpopulation binding a functional prothrombinase. Arterioscler Thromb Vasc Biol 30(12):2400–2407

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Li Y et al (2010) Levels of main platelet thrombin receptors in older chronic haemodialysis patients. Chin Med J (Engl) 123(17):2495–2496

    Google Scholar 

  29. Li Y et al (2011) Effects of Salivae Miltiorrhizae Liguspyragine Hydrochloride and Glucose Injection on the levels of main platelet thrombin receptors in chronic haemodialysis patients. Chin J Integr Med 17(8):625–630

    Article  CAS  PubMed  Google Scholar 

  30. Feldman HI, Kobrin S, Wasserstein A (1996) Hemodialysis vascular access morbidity. J Am Soc Nephrol 7(4):523–535

    CAS  PubMed  Google Scholar 

  31. Capodanno D, Angiolillo DJ (2012) Antithrombotic therapy in patients with chronic kidney disease. Circulation 125(21):2649–2661

    Article  PubMed  Google Scholar 

  32. Polzin A et al (2016) Antiplatelet effects of aspirin in chronic kidney disease patients. J Thromb Haemost 14(2):375–380

    Article  CAS  PubMed  Google Scholar 

  33. Small DS et al (2009) Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease. J Clin Pharm Ther 34(5):585–594

    Article  CAS  PubMed  Google Scholar 

  34. Butler K, Teng R (2012) Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. J Clin Pharmacol 52(9):1388–1398

    Article  CAS  PubMed  Google Scholar 

  35. Park SH et al (2009) A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 104(9):1292–1295

    Article  CAS  PubMed  Google Scholar 

  36. Angiolillo DJ et al (2010) Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 55(11):1139–1146

    Article  CAS  PubMed  Google Scholar 

  37. Kosoglou T et al (2012) Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease. Eur J Clin Pharmacol 68(7):1049–1056

    Article  CAS  PubMed  Google Scholar 

  38. Schror K (2002) The pharmacology of cilostazol. Diabetes Obes Metab 4(Suppl 2) pp S14–S19

    Article  CAS  PubMed  Google Scholar 

  39. Muller C et al (2012) Association of estimated GFR with platelet inhibition in patients treated with clopidogrel. Am J Kidney Dis 59(6):777–785

    Article  CAS  PubMed  Google Scholar 

  40. Mallikaarjun S, Forbes WP, Bramer SL (1999) Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites. Clin Pharmacokinet 37(Suppl 2):pp 33–40

    Article  CAS  PubMed  Google Scholar 

  41. Vane JR, Botting RM (2003) The mechanism of action of aspirin. Thromb Res 110(5–6):255–258

    Article  CAS  PubMed  Google Scholar 

  42. Antithrombotic Trialists C et al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678):1849–1860

    Article  Google Scholar 

  43. Jardine MJ et al (2010) Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol 56(12):956–965

    Article  CAS  PubMed  Google Scholar 

  44. Antithrombotic Trialists C (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329):71–86

    Article  Google Scholar 

  45. Antiplatelet Trialists’ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy–I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308(6921):pp 81–106

    Article  Google Scholar 

  46. Ethier J et al (2007) Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 50(4):602–611

    Article  PubMed  Google Scholar 

  47. McCullough PA et al (2002) Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 144(2):226–232

    Article  CAS  PubMed  Google Scholar 

  48. Best PJ et al (2008) The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 155(4):687–693

    Article  CAS  PubMed  Google Scholar 

  49. Keltai M et al (2007) Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil 14(2):312–318

    Article  PubMed  Google Scholar 

  50. Wiviott SD et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357(20):2001–2015

    Article  CAS  PubMed  Google Scholar 

  51. Roe MT et al (2012) Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 367(14):1297–1309

    Article  CAS  PubMed  Google Scholar 

  52. James S et al (2010) Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 122(11):1056–1067

    Article  PubMed  Google Scholar 

  53. Magnani G et al (2015) Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc 4(3):e001505

    Article  PubMed  PubMed Central  Google Scholar 

  54. Morrow DA et al (2012) Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366(15):1404–1413

    Article  CAS  PubMed  Google Scholar 

  55. Tricoci P et al (2012) Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 366(1):20–33

    Article  CAS  PubMed  Google Scholar 

  56. Lim PS et al (2016) Role of Cilostazol Therapy in Hemodialysis Patients with Asymptomatic Peripheral Arterial Disease: A Retrospective Cohort Study. Biomed Res Int 2016:8236903

    PubMed  PubMed Central  Google Scholar 

  57. Bangalore S et al (2014) Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open Heart 1(1):e000068

    Article  PubMed  PubMed Central  Google Scholar 

  58. Park KW et al (2013) Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen). JACC Cardiovasc Interv 6(9):932–942

    Article  PubMed  Google Scholar 

  59. Youn YJ et al (2014) Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease. Am Heart J p. 241–248(2):e1

    Google Scholar 

  60. Levey AS et al (1998) Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32(5):853–906

    Article  CAS  PubMed  Google Scholar 

  61. Charytan D, Kuntz RE (2006) The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 70(11):2021–2030

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Price MJ et al (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305(11):1097–1105

    Article  CAS  PubMed  Google Scholar 

  63. Collet JP et al (2011) Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. Am Heart J p. 5–12(1):e5

    Article  Google Scholar 

  64. Plantinga L et al (2011) Nonsteroidal anti-inflammatory drug use among persons with chronic kidney disease in the United States. Ann Fam Med 9(5):423–430

    Article  PubMed  PubMed Central  Google Scholar 

  65. Jankovic SM et al (2009) Nonsteroidal antiinflammatory drugs and risk of gastrointestinal bleeding among patients on hemodialysis. J Nephrol 22(4):502–507

    CAS  PubMed  Google Scholar 

  66. Ibrahim H et al (2014) Association of immature platelets with adverse cardiovascular outcomes. J Am Coll Cardiol 64(20):2122–2129

    Article  PubMed  Google Scholar 

  67. Eikelboom JW, Warkentin TE (2014) Immature platelet count: part of the cardiologist’s complete blood count? J Am Coll Cardiol 64(20):2130–2132

    Article  PubMed  Google Scholar 

  68. Bufalino VJ et al (2011) The American Heart Association’s recommendations for expanding the applications of existing and future clinical registries: a policy statement from the American Heart Association. Circulation 123(19):2167–2179

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. New York University Langone Medical Center, 530 1st Ave skirball 9V, New York, NY, 10016, USA

    Homam Ibrahim

  2. Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA

    Sunil V. Rao

Authors
  1. Homam Ibrahim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sunil V. Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Homam Ibrahim.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ibrahim, H., Rao, S.V. Oral antiplatelet drugs in patients with chronic kidney disease (CKD): a review. J Thromb Thrombolysis 43, 519–527 (2017). https://doi.org/10.1007/s11239-017-1483-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-017-1483-3

Keywords

Search

Navigation